With the California-based drug manufacturer Gilead Sciences planning to roll out another hepatitis C medication, academics said Wednesday that policy changes are needed in the costly drug market so the interests of patients, health insurers and pharmaceutical companies align. Read More
In an effort to blunt the high price of hepatitis C treatments… Read More
A raft of new cancer drugs promise better, longer-lasting treatments with fewer adverse side effects -- but their high cost is a growing concern. Read More
Winston Churchill famously described an appeaser as "one who feeds a crocodile, hoping it will eat him last." Today, in a very different context, his remark captures the plight of the American pharmaceutical industry. Read More
After recording the best launch of any drug in history, it looks like the pace is starting to slow down for Gilead Sciences' Sovaldi — the new $84,000 hepatitis C cure that's sparking a new focus on specialty drug costs. Read More
Gilead should be commended for taking action to make their best-selling treatment for Hepatitis C, Sovaldi, available to more people around the world. In India, they’ve struck licensing agreements with generic firms to produce the product for pennies on the dollar. Unfortunately, Gilead’s largess is being funded largely on the backs of American families. Read More
Over the last several months there has been a 'plateau and downward trend' in the use of Gilead Sciences Inc's controversial $1,000-a-pill hepatitis C treatment, Sovaldi, a CVS Health Corp analysis showed. Read More
Gilead announced that it had struck agreements with seven Indian generic drug makers to sell lower-cost versions of its $1,000-a-pill Hepatitis C drug in poorer countries. The deals are intended to provide greater access to the medicine Sovaldi for most of the nearly 180 million infected worldwide with Hepatitis C who do not live in rich countries. Some 350,000 people die every year of Hepatitis C infections, most of them in middle- and low-income nations. Read More
Runaway drug pricing has become a recent hot topic, witnessed best by the media and political bashing of Gilead Sciences (GILD_) for the $1,000-per-day cost of its hepatitis C pill Sovaldi. Read More
There are a lot of innovative therapies with encouraging prospects and eye-popping price tags in the news lately. All of them pose hard questions about the big commercial risks drug companies must take and the enormous pricing power of medicines that can help suffering patients. Read More
The state of Iowa has started paying $1,000 per pill for a new drug targeting hepatitis C, but officials don't plan to buy the medication for every person who carries the virus and qualifies for public health care. Read More
Gilead Sciences Inc. (GILD) is close to a pact with generic drugmakers to bring low-cost versions of its $84,000 hepatitis C drug Sovaldi to about 80 developing countries including India,Indonesia, and Pakistan. Read More